Characterization of patients with refractory or unexplained chronic cough participating in a Phase 2 clinical trial of the P2X3-receptor antagonist gefapixant

Tuesday, January 25th, 2022

This study examined the clinical characteristics of patients with refractory chronic cough or unexplained chronic cough enrolled in a multicenter, randomized, Phase IIb trial of gefapixant versus placebo. Cough-related characteristics were measured at baseline, and included objective awake cough frequency and patient-reported outcomes. 24-Hour objective cough frequency was measured using the Vitalograph VitaloJAK acoustic recording device.